Biotechnology Letters

, Volume 36, Issue 9, pp 1761–1769 | Cite as

Section: bioprocessing and biological engineering gene fragment polymerization for increased yield of recombinant HIV fusion inhibitor enfuvirtide

  • Anil Gudipudi
  • Chitra Bajji
  • Ravikanth Reddy Kosana
  • Kalpana Panati
  • Dakshayani Lomada
  • Venkat R. R. Arva Tatireddigari
  • Venkata Ramireddy Narala
Original Research Paper
First Online:
Received:
Accepted:
  • 211 Downloads

Abstract

Fuzeon (Enfuvirtide, T20) is the first fusion inhibitor approved by the FDA of the USA for the treatment of HIV/AIDS in combination with other anti-retroviral drugs. Enfuvirtide is a synthetic peptide that blocks the entry of HIV into healthy host CD4 cells, which requires very high (90 mg twice daily) therapeutic doses. To increase the yield of Enfuvirtide, a gene polymerization strategy was introduced and recombinant T20 (rT20) was expressed in Escherichia coli as a five copy repeat polypeptide with a histidine-tag. The five copy rT20 was purified by Ni-affinity chromatography and cleaved to single rT20 units by cyanogen bromide. Finally, single rT20 units were purified by reversed phase chromatography giving a yield (400 mg/l) with a purity >95 %, which exhibited specific biological activity similar to Fuzeon.

Keywords

Enfuvirtide Fuzeon Gene fragment polymerization HIV/AIDS Recombinant T20 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by Department of Biotechnology, New Delhi, India. All authors would like to acknowledge the continuous support of Dr. Murali Tummuru, Director, Virchow Biotech Pvt. Ltd., Hyderabad, India.

Conflict of interests

The authors declare to have no conflicts of interest.

References

  1. Andreev YA, Kozlov SA, Vassilevski AA, Grishin EV (2010) Cyanogen bromide cleavage of proteins in salt and buffer solutions. Anal Biochem 407:144–146PubMedCrossRefGoogle Scholar
  2. Blachinsky E, Marbach I, Cohen R, Grably MR, Engelberg D (2004) Procedure for controlling number of repeats, orientation, and order during cloning of oligonucleotides. Biotechniques 36:933–936PubMedGoogle Scholar
  3. Bray BL (2003) Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2:587–593PubMedCrossRefGoogle Scholar
  4. Carlos Rodrígue J, Wong L, Jennings PA (2003) The solvent in CNBr cleavage reactions determines the fragmentation efficiency of ketosteroid isomerase fusion proteins used in the production of recombinant peptides. Protein Expr Purif 28:224–231CrossRefGoogle Scholar
  5. Fung HB, Guo Y (2004) Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352–378PubMedCrossRefGoogle Scholar
  6. Gardella TJ, Rubin D, Abou-Samra AB, Keutmann HT, Potts JT Jr, Kronenberg HM, Nussbaum SR (1990) Expression of human parathyroid hormone-(1-84) in Escherichia coli as a factor X-cleavable fusion protein. J Biol Chem 265:15854–15859PubMedGoogle Scholar
  7. Jobbagy Z, Ward JL, Toan SV, Leung GP, Tse CM (2002) One-step unidirectional cloning of tandem repeats of DNA fragments: an application for fusion protein production. Anal Biochem 303:104–107PubMedCrossRefGoogle Scholar
  8. Jonasson P, Nygren P-Å, Johansson B-L, Wahren J, Uhlén M, Ståhl S (1998) Gene fragment polymerization gives increased yields of recombinant human proinsulin C-peptide. Gene 210:203–210PubMedCrossRefGoogle Scholar
  9. Kaiser R, Metzka L (1999) Enhancement of cyanogen bromide cleavage yields for methionyl-serine and methionyl-threonine Peptide Bonds. Anal Biochem 266:1–8PubMedCrossRefGoogle Scholar
  10. Karumuri NN, Gangireddy SR, Narala VR, Majee SS, Gunwar S, Reddy RC (2007) Simple, rapid, high-purity preparation of recombinant human platelet-derived growth factor-BB. Biotechnol Lett 29:1333–1339PubMedCrossRefGoogle Scholar
  11. Kosana RR, Bajji C, Kanumuri RM, Panati K, Mangamoori LN, Tummuru MR, Narala VR (2014) Recombinant approach for the production of HIV fusion inhibitor enfuvirtide using Escherichia coli. Protein Expr Purif 95:136–142PubMedCrossRefGoogle Scholar
  12. Reddy PK, Reddy SG, Narala VR, Majee SS, Konda S, Gunwar S, Reddy RC (2007) Increased yield of high purity recombinant human interferon-gamma utilizing reversed phase column chromatography. Protein Expr Purif 52:123–130PubMedCentralPubMedCrossRefGoogle Scholar
  13. Shen SH (1984) Multiple joined genes prevent product degradation in Escherichia coli. Proc Natl Acad Sci USA 81:4627–4631PubMedCentralPubMedCrossRefGoogle Scholar
  14. Smith DB, Johnson KS (1988) Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31–40PubMedCrossRefGoogle Scholar
  15. Sørensen HP, Mortensen KK (2005) Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 115:113–128PubMedCrossRefGoogle Scholar
  16. Zhao DX, Ding ZC, Liu YQ, Huang ZX (2007) Overexpression and purification of single zinc finger peptides of human zinc finger protein ZNF191. Protein Expr Purif 53:232–237PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Anil Gudipudi
    • 1
  • Chitra Bajji
    • 1
  • Ravikanth Reddy Kosana
    • 1
  • Kalpana Panati
    • 2
  • Dakshayani Lomada
    • 3
  • Venkat R. R. Arva Tatireddigari
    • 4
  • Venkata Ramireddy Narala
    • 4
  1. 1.Virchow Research CenterHyderabadIndia
  2. 2.Department of BiotechnologyGovernment College for MenKadapaIndia
  3. 3.Department Genetics & GenomicsYogi Vemana UniversityKadapaIndia
  4. 4.Department of ZoologyYogi Vemana UniversityKadapaIndia

Personalised recommendations